IP Library Granted Patent US 11,857,525
Granted Patent B2
US 11,857,525 · App. 15/548,186 · Granted Jan 2, 2024

Treatment or prevention of surgery-induced cachexia and/or expression of myeloid-derived suppressor cells and pro-inflammatory cytokines

Inventors: Jill Hamilton-Reeves (Shawnee, KS); Jeffrey M. Holzbeierlein (Mission Hills, KS); Thomas Yankee (Overland Park, KS)
Assignee: Societe des Produits Nestle S.A.
A61K31/198A23L33/12A23L33/13A23L33/14A23L33/155A23L33/175A23L33/30A61K9/0053A61K9/0095A61K31/07A61K31/202A61K31/70A61K31/7088A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,857,525
App. No.
15/548,186
Granted
Jan 2, 2024
Kind
B2
Abstract

A specialized immunonutrition supplement can be administered to a surgical patient to reduce post-operative complications by restraining the expansion of myeloid-derived suppressor cells. The supplement includes one or more of L-arginine, omega-3 fatty acids, vitamin A, and dietary nucleotides, preferably all four of these compounds. The supplement is administered to the patient at least once per day for a time period extending from a pre-operative day that is three to seven days prior to a bladder surgery of the patient to a post-operative day that is three to seven days after the bladder surgery. The supplement can be administered to treat or prevent post-operative paralytic ileus in a bladder cancer patient; treat or prevent surgery-induced, inflammation-induced or cancer-induced cachexia; reduce the incidence of chronic infections resulting from expansion of myeloid-derived suppressor cells in a patient; and/or reduce mRNA expression of pro-inflammatory cytokines in a patient.

Claims (11)

1. A method of treating or preventing cachexia induced by at least one of surgery, cancer or infection in a patient who is an individual with bladder cancer scheduled to undergo a radical cystoprostatectomy, the method comprising administering to the patient a specialized immunonutrition supplement comprising a combination of L-arginine, omega-3 fatty acids, vitamin A, and nucleotides, and

the specialized immunonutrition supplement is administered to the patient in a daily dose that provides an amount of the omega-3 fatty acids that comprises about 0.5 g to about 10.0 g of eicosapentaenoic acid and docosahexaenoic acid in total per day and that provides at least about 500 μg RE of the vitamin A per day; and

the specialized immunonutrition supplement is administered to the patient at least once per day for a time period extending from a pre-operative day that is three to seven days prior to the radical cystoprostatectomy to a post-operative day that is three to seven days after the radical cystoprostatectomy.

2. The method of claim 1 , wherein the cachexia is induced by infection.

3. The method of claim 1 , wherein the specialized immunonutrition supplement is administered to the patient in a daily dose that provides between about 5 g and about 30 g of the L-arginine per day.

4. The method of claim 1 , wherein the specialized immunonutrition supplement is administered to the patient in a daily dose that provides an amount of the omega-3 fatty acids that comprises about 1.0 g to about 5.0 g of eicosapentaenoic acid and docosahexaenoic acid in total per day.

5. The method of claim 1 , wherein the specialized immunonutrition supplement is administered to the patient in a daily dose that provides between about 0.5 mg and about 10.0 mg of the nucleotides per day.

6. The method of claim 1 , wherein at least a portion of the nucleotides are provided by polymeric yeast RNA and/or derived from yeast RNA.

7. The method of claim 1 , wherein the specialized immunonutrition supplement is orally administered to the patient.

8. The method of claim 1 , wherein the specialized immunonutrition supplement further comprises an additional component selected from the group consisting of a protein, a carbohydrate, a lipid, and mixtures thereof.

9. The method of claim 1 , wherein the bladder cancer is associated with a tumor.

Assignments (6)
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0001 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0165 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ENGLISH TRANSLATION TO SHOW THE FULL AND CORRECT NEW NAME IN SECTION 51. PREVIOUSLY RECORDED AT REEL: 049391 FRAME: 0756. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER. Recorded Jun 13, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049853/0398 →
MERGER Recorded Jun 6, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049391/0756 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2017
From: UNIVERSITY OF KANSAS
To: NESTEC S.A.
Reel/Frame 044443/0176 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2017
From: HAMILTON-REEVES, JILL; HOLZBEIERLEIN, JEFFREY M.; YANKEE, THOMAS
To: UNIVERSITY OF KANSAS
Reel/Frame 043904/0046 →